SUMMARY The prevalence of peripheral polyneuropathy in patients with monoclonal gammopathy is known to be higher than in the general population. A prevalence as high as that in the series of Osby etal, who found clinical and/or electrophysiological evidence compatible with peripheral polyneuropathy in 15 of 21 patients has not been reported before. These results could not be confirmed in a study in which 19 patients with benign monoclonal gammopathy were investigated. In contrast there were only two patients with questionable evidence of peripheral neuropathy: one had lower limb symptoms and signs only, the other had evidence of a subclinical polyneuropathy with some abnormalities of nerve conduction.
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We were surprised by the high incidence of peripheral polyneuropathy found in patients with benign monoclonal gammopathy in the series of Osby et al.' We therefore examined 19 similar patients for the presence of peripheral polyneuropathy.
Patients and methods
Unselected consecutive patients who were known to have a monoclonal gammopathy, were asked to take part in the study. Patients were excluded if they were known or suspected to be suffering from another disease that might be associated with peripheral polyneuropathy. One patient (No 14) had a biclonal paraproteinaemia. All patients underwent thorough neurological and haematological evaluation, including serum and urine immunoelectrophoresis with typing of heavy and light chains, bone marrow aspirations and biopsies, and skeletal radiography. At the time of the study all patients were considered to have benign paraproteinaemia (however, one patient, No 9, admitted because of radiographic chest abnormalities thought to be caused by fungal infection and who was considered to have benign paraproteinaemia, proved to be suffering from pulmonary amyloidosis at necropsy six months later. Bone marrow examination after death was compatible with multiple myeloma, in contrast to the examination during life).
Electromyographic and electroneurographic studies were performed in a warm, dry room with the patient supine. Needle electromyography was performed with concentric needle electrodes. Spontaneous activity (fibrillations and positive sharp waves and motor unit action potentials) were analysed subjectively. In all patients maximal motor and sensory nerve conduction velocities were measured orthodromically in the median nerve. In one patient (No 19) the same was done in the tibial nerve. The nerves were stimulated with needle electrodes.2 The compound muscle action potential was recorded with surface electrodes. Sensory nerve action potentials were recorded with needle electrodes at wrist and elbow after stimulation of the digital nerves of the thumb. All responses were photographed for subsequent analysis. Conduction velocities and distal motor latencies were determined in conventional fashion. The values were corrected for the influence of temperature, measured near the nerve at the site of stimulation with a needle electrode. The findings were compared to age-equilibrated normal values3 and differences of the mean value minus two standard deviations were judged to be pathological. The amplitude of the sensory nerve action potential was measured from peak to peak.
Results
The results of the clinical, haematological and neurophysiological examinations are summarised in 706
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